Articles tagged with: pre-exposure prophylaxis (PrEP)

Many Americans still get their HIV diagnosis years after infection

published: December, 07, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, As Prevention , Gay Men, Treatment Guidelines -including when to start, Research, Health, Revolving Door, International , Treatment, Guest Authors, Media

Heterosexual men had undiagnosed HIV longer than women who inject drugs or gay and bisexual men (a median of about five years, two years and three years, respectively).From AIDSmap, Liz Highleyman reports.

Many Americans still get their HIV diagnosis years after infection

Many people with HIV in the United States are still being diagnosed with HIV late, and therefore not getting the full therapeutic and prevention benefits of starting antiretroviral therapy (ART) early, according to the latest Vital Signs report from the US Centers for Disease Control and Prevention (CDC), released in advance of World AIDS Day. People at risk for HIV in the US are getting tested more often than they did in the past and are living with HIV for a shorter period of time bef

Creating a comprehensive cascade: CTAC issues call to action

published: December, 01, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, Activism, As Prevention , Current Affairs, Treatment Guidelines -including when to start, Research, Health, Revolving Door, Treatment, Guest Authors, Living with HIV, Media

To achieve and exceed the three 90-90-90-targets, two new targets are proposed

Creating a comprehensive cascade: CTAC issues call to action

As we approach World AIDS Day on December 1, CTAC is sending a strong message that “we’re not going away” by reaching out to select policymakers and their critics at all levels of government across Canada. We are providing them with an update on the issues of access to HIV and HCV treatment and care across Canada. CTAC was created by HIV positive leaders in 1996 to ensure access to treatment, care and support for people living with HIV/AIDS and people living with HIV/hepatitis C co-infe

What’s next for long-acting HIV drugs?

published: November, 22, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // CATIE, As Prevention , Current Affairs, Treatment Guidelines -including when to start, Research, CATIE - HIV and Hep C Info Resource, Health, Treatment

Two phase III trials are underway with long-acting (LA) formulations of HIV drugs. From CATIE, Sean R. Hosein reports.

What’s next for long-acting HIV drugs?

Two phase III trials are underway with long-acting (LA) formulations of HIV drugs. These trials will explore the safety and effectiveness of LA formulations in people new to HIV treatment (Flair) and in people who are treatment experienced (Atlas). The interim results from these two pivotal studies should be available in the latter half of 2018. If the results from Flair and Atlas are favourable, the manufacturer of the LA drugs, Viiv Healthcare, will submit a dossier of the data to regulator

World AIDS Day: Clients can handle the truth

published: November, 16, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // African, Caribbean and Black, Social Media, Activism, As Prevention , Gay Men, CATIE, Current Affairs, General Health, Treatment Guidelines -including when to start, Mental Health, Research, Women, Sexual Health, CATIE - HIV and Hep C Info Resource, Health, Treatment, Media

CATIE: "Whether we are talking about U=U, PrEP or HIV self-testing, we must provide all the information and options to our clients, and trust them to make the best decisions for their own health."

World AIDS Day: Clients can handle the truth

Thousands of HIV organizations around the world are adding a new message to their World AIDS Day campaigns this year, and it is turning decades of HIV prevention messaging on its head. We can now say conclusively that a person living with HIV who takes treatment and maintains an undetectable viral load does not transmit the virus to their sexual partners. The evidence was solidified last year with the final results of PARTNER and HPTN 052, two large studies confirming zero cases of HIV transm

BC just lost its last two excuses not to cover the pill that prevents HIV

published: November, 14, 2017 Written by // Guest Authors - Revolving Door Categories // Gay Men, As Prevention , Current Affairs, Treatment Guidelines -including when to start, Health, Revolving Door, Legal, Treatment, Guest Authors, Media

New proposal would cover 5,000 PrEP prescriptions by 2019. From Daily Xtra.com, Niko Bell reports.

BC just lost its last two excuses not to cover the pill that prevents HIV

Rob Higgins from the Community Based Research Centre and William Flett from YouthCO give out flyers in front of Vancouver-West End MLA Spencer Chandra Herbert's office Nov 10, 2017, pushing for provincial coverage for PrEP drugs. Credit: Niko Bell/Xtra To read the complete story by Niko Bell, visit Daily Xtra.com, here. One of the province’s most respected HIV/AIDS specialists has publicly announced that coverage for an effective HIV-prevention drug doesn’t have to cost BC taxpayers a

New report from OHESI shows numbers of new HIV infections in Ontario continue to rise - but some good news as Toronto’s continue to fall.

published: November, 10, 2017 Written by // Bob Leahy - Publisher Categories // OHTN OHTN/PositiveLite.com, Social Media, As Prevention , Gay Men, Current Affairs, Treatment Guidelines -including when to start, Mental Health, Research, Health, Treatment, Ontario HIV Treatment Network, Media, Bob Leahy - Publisher

Bob Leahy on the mixed bag of numbers which shows a province struggling to match impressive gains elsewhere. Where is this all heading?

New report from OHESI shows numbers of new HIV infections in Ontario continue to rise - but some good news as Toronto’s continue to fall.

PositiveLite.com previewed the numbers before, but now the preliminary report  is out and it’s a mixed bag. One thing is clear though. Ontario is being left behind by some of its competition. The province’s epidemiology unit, OHESI, housed at the OHTN, confirms that new HIV infections, although down from ten years ago, have been on the rise the last three years. The increase in that time period is fortunately not large but contrasts sharply with good news from other countries, notabl

A year of generic PrEP could recoup its own cost within five years if effectiveness is high, Public Health England model finds

published: October, 26, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, As Prevention , Gay Men, Treatment Guidelines -including when to start, Health, Revolving Door, International , Treatment, Guest Authors, Media

From AIDSmap, Gus Cairns reports on the findings of a cost-effectiveness model developed by Public Health England.

A year of generic PrEP could recoup its own cost within five years if effectiveness is high, Public Health England model finds

A cost-effectiveness model developed by Public Health England finds that just one year’s worth of pre-exposure prophylaxis (PrEP), given to gay men during a period of moderate to high HIV risk, would recoup its own costs and save the NHS money within 23 years if PrEP effectiveness was as high as that seen in the PROUD study – and if PrEP drug prices remained at the current level. However, if drug prices fell by 90% as a result of the availability of generics, one year of PrEP would recoup

What I've learned through training

published: October, 13, 2017 Written by // Megan DePutter Categories // Social Media, As Prevention , Gay Men, General Health, Treatment Guidelines -including when to start, Women, Health, International , Treatment, Living with HIV, Media, Megan DePutter, Opinion Pieces

Megan DePutter reflects on some of the high points as she prepares to go on maternity leave.

What I've learned through training

I’ve spent the last 1.5 years delivering training on HIV and related topics in Scotland. The audience has been diverse – it’s included nurses, GP’s, infant feeding advisors, midwives, therapists, social workers, addictions and criminal justice workers, dieticians and occupational therapists, psychologists, early childcare workers, people who work with vulnerable adults, students and people in a wide variety of other roles! During this period I’ve delivered training for nearly 550 peo

Many gay/bisexual men currently taking PrEP would switch to injectable forms of the therapy should it become available

published: October, 12, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, African, Caribbean and Black, As Prevention , Gay Men, Treatment Guidelines -including when to start, Research, Sexual Health, Health, Revolving Door, International , Treatment, Guest Authors, Media

"It removes the requirement to take daily treatment and the need to maintain high levels of treatment adherence." From AIDSmap, Michael Carter reports.

Many gay/bisexual men currently taking PrEP would switch to injectable forms of the therapy should it become available

Approximately a third of gay and bisexual men who are currently taking oral (tenofovir/emtricitabine) pre-exposure prophylaxis (PrEP) would prefer long-acting injectable PrEP should it become available, investigators report in AIDS and Behavior. Individuals were less likely to prefer injectable PrEP if they had concerns about the level of protection it provided against HIV and/or about its durability. “About one-third of GBM [gay and bisexual men] currently taking oral PrEP would prefer LA

U.S. simulation explores the intersection of PrEP and some sexually transmitted infections

published: October, 10, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, As Prevention , Gay Men, CATIE, General Health, Treatment Guidelines -including when to start, Research, Health, Sexual Health, CATIE - HIV and Hep C Info Resource, Treatment, Lifestyle, Media

"The results of the researchers’ simulations show that PrEP should be considered as a package of interventions, of which STI screening and treatment are an important part. From Catie, Sean R. Hosein reports.

U.S. simulation explores the intersection of PrEP and some sexually transmitted infections

The use of medicines to prevent a person from becoming infected with HIV is called pre-exposure prophylaxis (PrEP). PrEP consists of two anti-HIV drugs—tenofovir DF and FTC—in one pill. In clinical trials with gay, bisexual and other men who have sex with men (MSM), PrEP has been highly effective in preventing the spread of HIV. According to a team of U.S. researchers who analysed data from several clinical trials, the consistent use of PrEP can reduce the risk of HIV infection “by more

[12 3 4 5  >>